reduce insulin dose when starting glp-1 receptor agonist Should a patient stop their long-acting (insulin glargine or detemir) a Glucagon-like peptide-1 (GLP-1) agonist, such as liraglutide? What are GLP-1s? | Mendinground

Thorsten Leucker among others: We are people serving people to promote health and alleviate suffering by delivering exceptional care, developing future leaders and driving innovation

Priority areas include prospective studies of gastric ultrasound findings, symptom-based risk prediction, dose-escalation risk, agent-specific comparisons, tirzepatide-specific perioperative data, and pediatric/adolescent populations

As with any therapeutic compound, application under physician guidance is recommended to ensure appropriate concentration and formulation

Bak, L.K

This guide explores the roles of glutathione, recommended dosages, and essential safety considerations for long-term supplementation